EUVIMEDEUVIMED entdecken
Fallbericht

Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis

Hong Zheng Mm, XiaoJiu Zha Mm

ONCOLOGY · 10.09.2026 · 40 (7)

DOI: 10.46883/2026.25921241 ↗

Kurz gefasst

Fallbericht in der Zeitschrift ONCOLOGY, online erschienen am 10.09.2026. Verfasst von Hong Zheng Mm und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Brain Neoplasms, Lung Neoplasms, Anaplastic Lymphoma Kinase, Adenocarcinoma of Lung. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer. STRN-ALK fusions are rare among the nonclassical ALK fusion types, and they pose problems diagnostically and therapeutically. A 50-year-old woman had a 2-year history of cough, sputum, and wheeze. Initial workup revealed a severe mixed ventilatory defect, and imaging demonstrated left lung obstruction with mediastinal lymphadenopathy. Bronchoscopy confirmed mucinous adenocarcinoma, and molecular testing revealed a rare STRN-ALK fusion. Because of the patient’s clinical deterioration and concurrent brain metastases diagnosis, ensartinib was started in conjunction with chemotherapy. The patient had a significant improvement in symptoms, including weight gain. Imaging showed a reduction in total tumor burden and no new lesions on follow-up. The results suggested that ensartinib provided central nervous system stability and long-term tumor control. This is unlike prior descriptive accounts of patients with STRN-ALK fusion lung adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsLung NeoplasmsAnaplastic Lymphoma KinaseAdenocarcinoma of LungPhenylurea CompoundsProtein Kinase InhibitorsHumansFemaleMiddle AgedOncogene Proteins, FusionPiperazinesPyridazines

Substanzen

Anaplastic Lymphoma KinaseALK protein, humanensartinibPhenylurea CompoundsProtein Kinase InhibitorsOncogene Proteins, FusionPiperazinesPyridazines

Zitieren

APA

Hong Zheng Mm, & XiaoJiu Zha Mm (2026). Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis. ONCOLOGY, 40(7). https://doi.org/10.46883/2026.25921241

Vancouver

Hong Zheng Mm, XiaoJiu Zha Mm. Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis. ONCOLOGY. 2026;40(7). doi:10.46883/2026.25921241

BibTeX
@article{HongZhengMm2026,
  author = {Hong Zheng Mm and XiaoJiu Zha Mm},
  title = {Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis},
  journal = {ONCOLOGY},
  year = {2026},
  volume = {40},
  number = {7},
  doi = {10.46883/2026.25921241}
}
Kostenlos starten →